Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin, galectin-3, or E-selectin and galectin-3 to ligands a disclosed. For example, heterobifunctional inhibitors of E-selectin and galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described.
Type:
Application
Filed:
December 28, 2018
Publication date:
December 24, 2020
Applicant:
GLYCOMIMETICS, INC.
Inventors:
John L. MAGNANI, John M. PETERSON, Arun K. SARKAR, Yusufbhai U. VOHRA, Hong-Woon YANG
Abstract: Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation.
Type:
Grant
Filed:
November 20, 2019
Date of Patent:
September 8, 2020
Assignee:
GLYCOMIMETICS, INC.
Inventors:
John L. Magnani, Arun K. Sarkar, Myung-Gi Baek, Frank E. Anderson, III, Yanhong Li
Abstract: Compounds, compositions, and methods for modulating in vitro and in vivo processes mediated by selectin binding. For example, heterobifunctional compounds that inhibit both E-selectins and P-selectins are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids). The compounds are of formula (Ia) wherein the substituents are as defined in the claims.
Abstract: Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation.
Type:
Application
Filed:
November 20, 2019
Publication date:
May 21, 2020
Applicant:
GlycoMimetics, Inc.
Inventors:
John L. MAGNANI, Arun K. SARKAR, Myung-Gi BAEK, Frank E. ANDERSON, III, Yanhong LI
Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed. For example, E-selectin antagonists are described and pharmaceutical compositions comprising at least one of the same.
Type:
Application
Filed:
March 12, 2018
Publication date:
April 30, 2020
Applicant:
GLYCOMIMETICS, INC.
Inventors:
John L MAGNANI, John M PETERSON, Arun K SARKAR, Yusufbhai U VOHRA, Myung-Gi BAEK
Abstract: Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation.
Type:
Grant
Filed:
September 19, 2017
Date of Patent:
January 7, 2020
Assignee:
GlycoMimetics, Inc.
Inventors:
John L. Magnani, Arun K. Sarkar, Myung-Gi Baek, Frank E. Anderson, III, Yanhong Li
Abstract: Compounds, compositions, and methods for treatment and/or prevention of cancer and inflammatory diseases, and for releasing cells such as stem cells (e.g., bone marrow progenitor cells) into circulating blood and enhancing retention of the cells in the blood are disclosed. For example, heterobifunctional compounds that inhibit both E-selectins and CXCR4 chemokine receptors are described and pharmaceutical compositions comprising at least one of the same.
Type:
Grant
Filed:
December 1, 2015
Date of Patent:
December 31, 2019
Assignee:
GLYCOMIMETICS, INC.
Inventors:
John L. Magnani, Arun K. Sarkar, John M. Peterson
Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed. For example, highly potent multimeric E-selectin antagonist are dessorbed and pharmaceutical compositions comprising at least one of the same.
Type:
Application
Filed:
October 6, 2017
Publication date:
August 1, 2019
Applicant:
GLYCOMIMETICS, INC.
Inventors:
John L. MAGNANI, John M. PETERSON, Myung-Gi BAEK
Abstract: Compositions and methods for the treatment of diseases, disorders, and/or conditions associated with the increased regulatory T lymphocyte cell (Treg cell) function, comprising the administration of T-cell checkpoint inhibitors in combination with E-selectin inhibitors, CXCR4 receptor inhibitors, and/or heterobifunctional inhibitors that comprise at least one E-selectin inhibitor linked to at least one CXCR4 receptor inhibitor, are disclosed.
Abstract: New methods for treating and/or preventing cardiovascular disease including, for example, myocardial infarction and atherosclerosis, by the use of at least one E-selectin inhibitor and compositions comprising the same are disclosed.
Abstract: Compounds, compositions, and methods for the diagnosis and/or treatment of medical conditions involving infections with and colonization by Pseudomonas bacteria including, for example, Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis are described.
Abstract: Compounds, compositions, and methods for modulating in vitro and in vivo processes mediated by selectin binding. For example, heterobifunctional compounds that inhibit both E-selectins and P-selectins are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids). The compounds are of formula (Ia) wherein the substituents are as defined in the claims.
Abstract: Methods and systems for identifying and treating patients with cancers that can bind E-selectin are disclosed. E-selectin-binding cancers are identified by their cell surface expression sialyl Le3 and sialyl Le3 carbohydrate epitopes, and such cancers can be identified by antibodies that bind to sialyl Lea/x, such as HECA-452. Such cancers can be treated with antagonists of E-selectin such as glycomimetic compounds and with immunotherapies targeting the cell surface carbohydrates containing the sialyl Lea/x domains to block and/or disrupt the binding of E-selectin.
Abstract: The disclosure provides a new source of peripheral blood naive/memory stem cells (i.e. (TN)/TSCM/TCM) T-cells with enhanced reconstitution potential and/or longer life spans. It discloses that this particular subset of T-cells can be mobilized by administration of at least one mobilizer in combination with at least one E-Seiectin inhibitor.
Type:
Application
Filed:
August 2, 2016
Publication date:
August 16, 2018
Applicant:
GlycoMimetics, Inc.
Inventors:
Rachel K. KING, John L. MAGNANI, Ingrid G. WINKLER
Abstract: Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation.
Type:
Application
Filed:
September 19, 2017
Publication date:
March 8, 2018
Applicant:
GlycoMimetics, Inc.
Inventors:
John L. MAGNANI, Arun K. SARKAR, Myung-Gi BAEK, Frank E. ANDERSON, III, Yanhong LI
Abstract: Methods are provided herein for use of E-selectin antagonists for mobilizing cells, such as hematopoietic cells, hematopoietic stem cells and progenitor cells, white blood cells, and malignant cells, and hematopoietic tumor cells from the bone marrow. More specifically, methods are provided for using E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers, and peptides for mobilizing cells from the bone marrow to the peripheral vasculature and tissues.
Abstract: Compounds, compositions, and methods for treatment and/or prevention of cancer and inflammatory diseases, and for releasing cells such as stem cells (e.g., bone marrow progenitor cells) into circulating blood and enhancing retention of the cells in the blood are disclosed. For example, heterobifunctional compounds that inhibit both E-selectins and CXCR4 chemokine receptors are described and pharmaceutical compositions comprising at least one of the same.
Type:
Application
Filed:
December 1, 2015
Publication date:
October 26, 2017
Applicant:
GlycoMimetics, Inc.
Inventors:
John L MAGNANI, Arun K. SARKAR, John M. PETERSON
Abstract: Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selection antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation.
Type:
Grant
Filed:
June 26, 2015
Date of Patent:
October 24, 2017
Assignee:
GlycoMimetics, Inc.
Inventors:
John L. Magnani, Arun K. Sarkar, Myung-Gi Baek, Frank E. Anderson, III, Yanhong Li
Abstract: Methods for treating and/or preventing mucositis comprising administering to a subject in need thereof an effective amount of at least one compound chosen from E-selectin antagonists, pharmaceutically acceptable salts of E-selectin antagonists, prodrugs of E-selectin antagonists, and pharmaceutically acceptable salts of prodrugs of E-selectin antagonists, and compositions comprising at least one of such compound.
Type:
Application
Filed:
September 29, 2014
Publication date:
October 19, 2017
Applicant:
GLYCOMIMETICS, INC.
Inventors:
John L. MAGNANI, John M. PETERSON, Ingrid G. WINKLER
Abstract: Compounds, compositions and methods are provided for treatment of diseases or complications associated therewith, in which a selectin plays a role. More specifically, particular glycomimetics and uses thereof are described. For example, use of particular glycomimetics for treating sickle cell disease or a cancer involving a selectin, or complications associated with either, is described.